Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Operations (2020 - 2021)

Design Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 9227000.0 for Q4 2021.

  • For Q4 2021, Cash from Operations fell 224.44% year-over-year to 9227000.0; the TTM value through Dec 2021 reached 29377000.0, down 238.87%, while the annual FY2025 figure was 54358000.0, 26.11% down from the prior year.
  • Cash from Operations for Q4 2021 was 9227000.0 at Design Therapeutics, down from 8164000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1307000.0 in Q2 2020 and bottomed at 9227000.0 in Q4 2021.